Company intelligence / Profile preview

VSPharmTech

Cambridge, MA, United Statesvspharmtech.com ↗

Ownership: Private
Development stage: Other

Overview

VSPharmTech is a clinical-stage biotech company focused on oncology, with its lead asset, VS‑101, an oral radiosensitizer currently in Phase II trials for head and neck cancer. The company has secured four IND approvals across Korea and the US and is developing three unlicensed anticancer drug candidates. It leverages technologies such as drug repurposing, real-world evidence, and artificial intelligence to optimize development[1][2][3].

Therapeutic areas: Oncology
Modalities: Small molecule (radiosensitizers, chemosensitizers)Designer drugs (as per patent filings)
Industry: Biotech

Drug pipeline

3 assets

VS-101

2 more assets in the full pipeline.

Request access →

Partnerships

JLABS incubation by Johnson & Johnson[3]

Beyond the preview

Go deeper on VSPharmTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSPharmTech.

Explore the full profile